Background Bone damage around the joints is one of the major pathophysiological mechanisms that leads to rheumatoid arthritis （RA） chronic disability.Serum tartrate-resistant acid phosphatase 5b （TRACP-5b） is secr...Background Bone damage around the joints is one of the major pathophysiological mechanisms that leads to rheumatoid arthritis （RA） chronic disability.Serum tartrate-resistant acid phosphatase 5b （TRACP-5b） is secreted by osteoclasts,its activity can be used as a clinically relevant bone resorption marker.The aim of this study was to test whether the measurement of serum levels of TRACP-5b in patients with RA would correlate with measures of disease activity and with responses to therapy.Methods Fifty-six patients were randomly assigned to receive recombinant human cytotoxic tlymphocyte-associated antigen-4 immunoglobulin （RhCTLA4-lg）,infliximab or methotrexate （MTX）.The clinical and serologic indicators of RA activity were evaluated at baseline and at 24 weeks.Serum TRACP-5b was measured by Enzyme-linked Immunosorbent Assay （ELISA） at 0,12 and 24 weeks.Hand X-rays were obtained at baseline.Results At baseline,the levels of TRACP-5b correlated with the severity of X-ray damage,disease duration （r=0.332,P=0.012）,and tender joint count （r=0.408,P=0.002）.The 24 weeks values of TRACP-5b for RhCTLA4-lg group and infliximab group differed significantly from the baseline values in each group （P 〈0.05; P 〈0.05）,whereas only the value for RhCTLA4-lg group differed significantly from the 24 weeks value for the MTX group （P 〈0.01）.Considering the two biologics-treated groups together,the TRACP-5b levels at 24 weeks differed significantly from the baseline values only in those patients who reached an ACR70 level （P 〈0.05）.Conclusions Measurement of serum TRACP-5b in RA patients reflects clinical and radiological measures of disease activity,treatment with certain biologics,and degree of response to therapy.TRACP-5b should be investigated further as a potential biomarker to predict response to therapy,including slowing of radiographic progression.展开更多
通过对双角山羊草紫色酸性磷酸酶PAP1基因的核酸和氨基酸序列进行相关生物信息学分析,旨在进一步利用基因工程手段将Ae Bi PAP1基因转入到小麦中,为获得耐低磷胁迫能力增强的小麦品种提供种质基因。以双角山羊草叶片为材料,根据小麦中的...通过对双角山羊草紫色酸性磷酸酶PAP1基因的核酸和氨基酸序列进行相关生物信息学分析,旨在进一步利用基因工程手段将Ae Bi PAP1基因转入到小麦中,为获得耐低磷胁迫能力增强的小麦品种提供种质基因。以双角山羊草叶片为材料,根据小麦中的PAP1基因和二穗短柄草的PAP1基因设计兼并引物,采用同源克隆的方法,获得了双角山羊草紫色酸性磷酸酶PAP1基因的c DNA序列,并将其命名为Ae Bi PAP1,该双角山羊草紫色酸性磷酸酶PAP1基因长1.124 kb,共编码335个氨基酸,相应的氨基酸分子量为38.131 k Da,等电点为5.77。与小麦中的PAP1基因相比,双角山羊草PAP1的c DNA编码区发生碱基替代的地方共有35处,包含13处颠换与22处转换,有15处编码的氨基酸残基不同,其序列一致性达95.52%。对Ae Bi PAP1基因编码的蛋白质进行生物信息学分析发现,该蛋白具有一个信号肽但却没有跨膜结构,对Ae Bi PAP1编码蛋白进行三级结构预测发现,该编码蛋白包含金属离子结合中心,预测它属于金属蛋白。因此,将其定位于质膜比分泌到胞外的概率要高,通过对同源蛋白质氨基酸序列进行系统进化树分析,结果表明,双角山羊草紫色酸性磷酸酶PAP1基因与普通小麦的亲缘关系最近,与粳稻、短柄草、谷子亲缘关系较近,与大麦、乌拉尔图小麦、水稻以及节节麦等植物的亲缘关系较远。展开更多
Objective ：To evaluate the sensitivity of serum tartrate-resistant acid phosphatase 5b（Tracp5b） activity in monitoring bisphosphonate treatment results of bone metastasis in breast cancer（BC） patients. Methods：T...Objective ：To evaluate the sensitivity of serum tartrate-resistant acid phosphatase 5b（Tracp5b） activity in monitoring bisphosphonate treatment results of bone metastasis in breast cancer（BC） patients. Methods：The serum activities of Tracp5b, CEA, CA153 were measured in 58 BC patients, including 26 without bone metastasis, 32 with bone metastasis. The serum activities of TracpSb, CEA, CA153 were also measured in 19 patients with bone metastasis after 3 months of bisphosphonate treatment. Eighteen healthy women with age from 34 to 70 served as control. Results：Serum TracpSb was significantly elevated in patients with bone metastasis compared with that in all any other groups（P〈 0.05）. The sensitivity of TracpSb was 78.13% and the specificity was 86.36%. The sensitivity of CA153 was 37.50% and the specificity was 77.27%. The sensitivity of CEA was 21.88% and the specificity was 84.09%. The serum activity of TracpSb decreased significantly（P 〈 0.05） after 3 months of bisphosphonate treatment, while the levels of CA153 and CEA were unchanged. Conclusion：Serum Tracp5b activity is a useful diagnostic marker for bone metastasis in BC patients and can be used to evaluate the treatment results of bisphosphonate.展开更多
Objective： To find out the relationship of the expressions of proliferating cell nuclear antigen （proliferating cell nuclear antigen, PCNA）, alkaline phosphotase （alkaline phosphotase, AKP） and acid phosphotase ...Objective： To find out the relationship of the expressions of proliferating cell nuclear antigen （proliferating cell nuclear antigen, PCNA）, alkaline phosphotase （alkaline phosphotase, AKP） and acid phosphotase （acid phosphotase, ACP） with the development of mouse fore stomach cancerization. Methods： The animal models, including the various stages during the development of NIH mouse fore stomach carcinoma, were made by N-Nitrososarcosineethylester （N-Nitrososarcosineethylester, NSEE）. The mice were sacrificed on the 14th, 28th, 42nd, 56th, 70th and 84th days respectively after mice were irrigated with NSEE. The fore stomach was taken out and dissected. The methods of histopathology, immunohistochemistry and isoenzyme electrophoresis were adopted to study the dynamic changes of cell shape and expression of PCNA, AKP and ACP. Results： On the 42nd and 56th days after NSEE treatment, the expression of PCNA increased gradually along with the cancerization. Comparing with the control, there were significant differences （P〈0.05）. On the 70th and 84th days, the expression of PCNA increased further （compared with the control P〈0.01）. The activity of AKP increased gradually along with the cancerization. On the 14th, 28th, 42nd and 56th days, there were significant differences （P〈0.05）; on the 70th and 84th days, the activity of AKP increased further （P〈0.01）. The activity of ACP also increased on the 14th, 28th, 42nd and 56th days, and there were significant differences on the 70th days （P〈0.05） and on the 84th days （P〈0.01） compared with the control. Conclusion： During the carcinogenesis of NIH mouse fore stomach, the expressions of PCNA, AKP and ACP increased gradually and were consisted with the changes of cell shapes.展开更多
Objective： To observe effects of the drug-containing serum ofBu Shen Zhuang Gu Capsule （BSZGC 补肾壮骨胶囊 Capsule for Tonifying the Kidney to Strengthen the Bones） on proliferation of the rat＇s osteoclasts and ta...Objective： To observe effects of the drug-containing serum ofBu Shen Zhuang Gu Capsule （BSZGC 补肾壮骨胶囊 Capsule for Tonifying the Kidney to Strengthen the Bones） on proliferation of the rat＇s osteoclasts and tartrate-resistant acid phosphatase （TRACP） activity in vitro so as to delve into the mechanisms of its preventive and therapeutic actions on osteoporosis. Methods： Forty female Sprague-Dawley rats aged three months were randomly divided into high dosage BSZGC group, medium dosage BSZGC group, low dosage BSZGC group, and the control group. BSZGC was orally administered into the rats of high, medium, and low dosage groups at different dosages for 12 days, and isometric normal saline was orally administered to the rats of the control group. The drug-containing serum and control serum were prepared. Osteoclasts isolated mechanically from the femur and tibia of Sprague-Dawley rats aged one week were cultured with medium added with different drug-containing sera and control serum. The growth of osteoclasts was observed under an inverted phase-contrast microscope, and optic density （OD） value of osteoclasts was determined by MTT colorimetric assay. TRACP activity was measured by the diazol method. Results： OD value of osteoclasts in the high dosage drug-containing serum group, medium dosage drug-containing serum group, and low dosage drug-containing serum group was significantly lower than that in the control serum group （P〈0.05） with a dose-effect correlation. TRACP activity in high dosage drug-containing serum group, medium dosage drug-containing serum group, low dosage drug-containing serum group was significantly lower than that of the control serum group （P〈0.01）, and no significant differences in TRACP activity were not found among the different dosages drug-containing serum groups. Conclusions： BSZGC can inhibit the proliferation of the osteoclasts and reduce TRACP activity, which may be one of the mechanisms of its preventive and theraoeutic actions on osteooorosis.展开更多
文摘Background Bone damage around the joints is one of the major pathophysiological mechanisms that leads to rheumatoid arthritis （RA） chronic disability.Serum tartrate-resistant acid phosphatase 5b （TRACP-5b） is secreted by osteoclasts,its activity can be used as a clinically relevant bone resorption marker.The aim of this study was to test whether the measurement of serum levels of TRACP-5b in patients with RA would correlate with measures of disease activity and with responses to therapy.Methods Fifty-six patients were randomly assigned to receive recombinant human cytotoxic tlymphocyte-associated antigen-4 immunoglobulin （RhCTLA4-lg）,infliximab or methotrexate （MTX）.The clinical and serologic indicators of RA activity were evaluated at baseline and at 24 weeks.Serum TRACP-5b was measured by Enzyme-linked Immunosorbent Assay （ELISA） at 0,12 and 24 weeks.Hand X-rays were obtained at baseline.Results At baseline,the levels of TRACP-5b correlated with the severity of X-ray damage,disease duration （r=0.332,P=0.012）,and tender joint count （r=0.408,P=0.002）.The 24 weeks values of TRACP-5b for RhCTLA4-lg group and infliximab group differed significantly from the baseline values in each group （P 〈0.05; P 〈0.05）,whereas only the value for RhCTLA4-lg group differed significantly from the 24 weeks value for the MTX group （P 〈0.01）.Considering the two biologics-treated groups together,the TRACP-5b levels at 24 weeks differed significantly from the baseline values only in those patients who reached an ACR70 level （P 〈0.05）.Conclusions Measurement of serum TRACP-5b in RA patients reflects clinical and radiological measures of disease activity,treatment with certain biologics,and degree of response to therapy.TRACP-5b should be investigated further as a potential biomarker to predict response to therapy,including slowing of radiographic progression.
文摘通过对双角山羊草紫色酸性磷酸酶PAP1基因的核酸和氨基酸序列进行相关生物信息学分析,旨在进一步利用基因工程手段将Ae Bi PAP1基因转入到小麦中,为获得耐低磷胁迫能力增强的小麦品种提供种质基因。以双角山羊草叶片为材料,根据小麦中的PAP1基因和二穗短柄草的PAP1基因设计兼并引物,采用同源克隆的方法,获得了双角山羊草紫色酸性磷酸酶PAP1基因的c DNA序列,并将其命名为Ae Bi PAP1,该双角山羊草紫色酸性磷酸酶PAP1基因长1.124 kb,共编码335个氨基酸,相应的氨基酸分子量为38.131 k Da,等电点为5.77。与小麦中的PAP1基因相比,双角山羊草PAP1的c DNA编码区发生碱基替代的地方共有35处,包含13处颠换与22处转换,有15处编码的氨基酸残基不同,其序列一致性达95.52%。对Ae Bi PAP1基因编码的蛋白质进行生物信息学分析发现,该蛋白具有一个信号肽但却没有跨膜结构,对Ae Bi PAP1编码蛋白进行三级结构预测发现,该编码蛋白包含金属离子结合中心,预测它属于金属蛋白。因此,将其定位于质膜比分泌到胞外的概率要高,通过对同源蛋白质氨基酸序列进行系统进化树分析,结果表明,双角山羊草紫色酸性磷酸酶PAP1基因与普通小麦的亲缘关系最近,与粳稻、短柄草、谷子亲缘关系较近,与大麦、乌拉尔图小麦、水稻以及节节麦等植物的亲缘关系较远。
文摘Objective ：To evaluate the sensitivity of serum tartrate-resistant acid phosphatase 5b（Tracp5b） activity in monitoring bisphosphonate treatment results of bone metastasis in breast cancer（BC） patients. Methods：The serum activities of Tracp5b, CEA, CA153 were measured in 58 BC patients, including 26 without bone metastasis, 32 with bone metastasis. The serum activities of TracpSb, CEA, CA153 were also measured in 19 patients with bone metastasis after 3 months of bisphosphonate treatment. Eighteen healthy women with age from 34 to 70 served as control. Results：Serum TracpSb was significantly elevated in patients with bone metastasis compared with that in all any other groups（P〈 0.05）. The sensitivity of TracpSb was 78.13% and the specificity was 86.36%. The sensitivity of CA153 was 37.50% and the specificity was 77.27%. The sensitivity of CEA was 21.88% and the specificity was 84.09%. The serum activity of TracpSb decreased significantly（P 〈 0.05） after 3 months of bisphosphonate treatment, while the levels of CA153 and CEA were unchanged. Conclusion：Serum Tracp5b activity is a useful diagnostic marker for bone metastasis in BC patients and can be used to evaluate the treatment results of bisphosphonate.
基金This work was supported by Henan Technologies R & D Project (No. 0424420043) and Henan Zoology Key Subject.
文摘Objective： To find out the relationship of the expressions of proliferating cell nuclear antigen （proliferating cell nuclear antigen, PCNA）, alkaline phosphotase （alkaline phosphotase, AKP） and acid phosphotase （acid phosphotase, ACP） with the development of mouse fore stomach cancerization. Methods： The animal models, including the various stages during the development of NIH mouse fore stomach carcinoma, were made by N-Nitrososarcosineethylester （N-Nitrososarcosineethylester, NSEE）. The mice were sacrificed on the 14th, 28th, 42nd, 56th, 70th and 84th days respectively after mice were irrigated with NSEE. The fore stomach was taken out and dissected. The methods of histopathology, immunohistochemistry and isoenzyme electrophoresis were adopted to study the dynamic changes of cell shape and expression of PCNA, AKP and ACP. Results： On the 42nd and 56th days after NSEE treatment, the expression of PCNA increased gradually along with the cancerization. Comparing with the control, there were significant differences （P〈0.05）. On the 70th and 84th days, the expression of PCNA increased further （compared with the control P〈0.01）. The activity of AKP increased gradually along with the cancerization. On the 14th, 28th, 42nd and 56th days, there were significant differences （P〈0.05）; on the 70th and 84th days, the activity of AKP increased further （P〈0.01）. The activity of ACP also increased on the 14th, 28th, 42nd and 56th days, and there were significant differences on the 70th days （P〈0.05） and on the 84th days （P〈0.01） compared with the control. Conclusion： During the carcinogenesis of NIH mouse fore stomach, the expressions of PCNA, AKP and ACP increased gradually and were consisted with the changes of cell shapes.
文摘Objective： To observe effects of the drug-containing serum ofBu Shen Zhuang Gu Capsule （BSZGC 补肾壮骨胶囊 Capsule for Tonifying the Kidney to Strengthen the Bones） on proliferation of the rat＇s osteoclasts and tartrate-resistant acid phosphatase （TRACP） activity in vitro so as to delve into the mechanisms of its preventive and therapeutic actions on osteoporosis. Methods： Forty female Sprague-Dawley rats aged three months were randomly divided into high dosage BSZGC group, medium dosage BSZGC group, low dosage BSZGC group, and the control group. BSZGC was orally administered into the rats of high, medium, and low dosage groups at different dosages for 12 days, and isometric normal saline was orally administered to the rats of the control group. The drug-containing serum and control serum were prepared. Osteoclasts isolated mechanically from the femur and tibia of Sprague-Dawley rats aged one week were cultured with medium added with different drug-containing sera and control serum. The growth of osteoclasts was observed under an inverted phase-contrast microscope, and optic density （OD） value of osteoclasts was determined by MTT colorimetric assay. TRACP activity was measured by the diazol method. Results： OD value of osteoclasts in the high dosage drug-containing serum group, medium dosage drug-containing serum group, and low dosage drug-containing serum group was significantly lower than that in the control serum group （P〈0.05） with a dose-effect correlation. TRACP activity in high dosage drug-containing serum group, medium dosage drug-containing serum group, low dosage drug-containing serum group was significantly lower than that of the control serum group （P〈0.01）, and no significant differences in TRACP activity were not found among the different dosages drug-containing serum groups. Conclusions： BSZGC can inhibit the proliferation of the osteoclasts and reduce TRACP activity, which may be one of the mechanisms of its preventive and theraoeutic actions on osteooorosis.
